Nature Medicine, Published online: 05 March 2026; doi:10.1038/s41591-026-04273-1
In this phase 2, randomized trial in early Alzheimer’s disease, the TREM2 agonistic antibody AL002 showed target engagement but did not meet the primary endpoint of change from baseline in Clinical Dementia Rating-Sum of Boxes score.
